Inventor · disambiguated record
Karl D. Normington
Also filed as: NORMINGTON KARL D
12 granted patents·13 pending applications·366 citations·filing 1996–2023
92Inventor score
Files withSIRTRIS PHARMACEUTICALS INC7METRO INT BIOTECH LLC6PALLEON PHARMACEUTICALS INC4UNIV TEXAS3HARVARD COLLEGE2
Top patents by PatentIndex Score
25 records- 0195US11878027B2Nicotinamide mononucleotide derivatives and their usesMETRO INT BIOTECH LLC·Filed 2022·Granted Jan 23, 2024·2 cites·13 claims
- 0295US10548913B2Nicotinamide mononucleotide derivatives and their usesMETRO INT BIOTECH LLC·Filed 2018·Granted Feb 4, 2020·18 cites·29 claims
- 0394US9919003B2Nicotinamide mononucleotide derivatives and their usesMETRO INT BIOTECH LLC·Filed 2017·Granted Mar 20, 2018·16 cites·37 claims
- 0494US9855289B2Nicotinamide mononucleotide derivatives and their usesMETRO INT BIOTECH LLC·Filed 2016·Granted Jan 2, 2018·19 cites·35 claims
- 0590US11464796B2Nicotinamide mononucleotide derivatives and their usesMETRO INT BIOTECH LLC·Filed 2019·Granted Oct 11, 2022·6 cites·12 claims
- 0688US6110707ARecombinant expression of proteins from secretory cell linesUNIV TEXAS·Filed 1997·Granted Aug 29, 2000·88 cites·41 claims
- 0787US12485135B2Nicotinamide mononucleotide derivatives and their usesMETRO INT BIOTECH LLC·Filed 2023·Granted Dec 2, 2025·0 cites·12 claims
- 0886US5854067AHexokinase inhibitorsUNIV TEXAS·Filed 1996·Granted Dec 29, 1998·96 cites·64 claims
- 0984US6087129ARecombinant expression of proteins from secretory cell linesBETAGENE INC·Filed 1996·Granted Jul 11, 2000·76 cites·26 claims
- 1082US6194176B1Recombinant expression of proteins from secretory cell linesUNIV TEXAS·Filed 1997·Granted Feb 27, 2001·43 cites·59 claims
- 1175US7998974B2Fused heterocyclic compounds and their use as sirtuin modulatorsSIRTRIS PHARMACEUTICALS INC·Filed 2006·Granted Aug 16, 2011·2 cites·16 claims
- 1273US11957703B2Modulating Nudix homology domain (NHD) with nicotinamide mononucleotide analogs and derivatives of sameHARVARD COLLEGE·Filed 2022·Granted Apr 16, 2024·0 cites·15 claims
- 1363US2015175645A1Nicotinamide riboside and analogues thereofGLAXOSMITHKLINE LLC·Filed 2014·Application pending·0 cites
- 1458US2019350960A1Modulating nudix homology domain (nhd) with nicotinamide mononucleotide analogs and derivatives of sameHARVARD COLLEGE·Filed 2018·Application pending·0 cites
- 1553US2006229265A1Nicotinamide riboside and analogues thereofSIRTRIS PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 1653US2021253695A1Use of siglec-7 or siglec-9 antibodies for the treatment of cancerPALLEON PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1750US2008249103A1Sirtuin polymorphisms and methods of use thereofSIRTRIS PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 1848US2006292099A1Treatment of eye disorders with sirtuin modulatorsMILBURN MICHAEL·Filed 2006·Application pending·0 cites
- 1945US2025049846A1Methods and compositions for treating cancer with immune cellsPALLEON PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2044US2009163476A1N-Phenyl Benzamide Derivatives as Sirtuin ModulatorsSIRTRIS PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 2143US2009069301A1Acridine and Quinoline Derivatives as Sirtuin ModulatorsSIRTRIS PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 2243US2007248590A1Modulators of CDC2-like kinases (CLKS) and methods of use thereofSIRTRIS PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
- 2342US2019023786A1Use of siglec-7 or siglec-9 antibodies for the treatment of cancerPALLEON PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2442US2022362351A1Recombinant sialidases and methods of using the samePALLEON PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2540US2006276393A1Novel compositions for preventing and treating neurodegenerative and blood coagulation disordersSIRTRIS PHARMACEUTICALS INC·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Karl D. Normington files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →